Top of this page
Skip navigation, go straight to the content
Cimzia® (certolizumab pegol) is a tumor necrosis factor (TNF) blocker indicated in the US for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
Warning: serious infections and malignancy
See full prescribing information for complete boxed warning.
In Switzerland, Cimzia® is indicated for the induction of a clinical response and for the maintenance of a clinical response and remission in patients with active Crohn's disease who have not responded adequately to conventional treatment.
For availability of Cimzia in other countries, please consult our local websites.